Growth of a human mammary tumor cell line is blocked by galangin, a naturally occurring bioflavonoid, and is accompanied by down-regulation of cyclins D3, E, and A

Breast Cancer Research

Volumn 8, Issue 2, 2006, Pages

  Murray, Tessa J ^a   Yang, Xinhai ^a   Sherr, David H ^a  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLEMETHANOL; ALPHA NAPHTHOFLAVONE; AROMATIC HYDROCARBON RECEPTOR; BIOFLAVONOID; CYCLIN A; CYCLIN D3; CYCLIN E; ESTROGEN RECEPTOR; GALANGIN; CCND3 PROTEIN, HUMAN; CYCLINE; FLAVONOID; MUTAGENIC AGENT;

ANALYSIS OF VARIANCE; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE CONSTRUCT; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; MITOSIS INHIBITION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPORTER GENE; WESTERN BLOTTING; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIN A; CYCLIN D3; CYCLIN E; CYCLINS; FEMALE; FLAVONOIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; MUTAGENS; TRANSFECTION;

EID: 33746564251     PISSN: 1465542X     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1391     Document Type: Article

References (88)

1. Formica J, Regelson W: Review of the biology of quercetin and related bioflavonoids. Food Chem Toxic 1995, 33:1061-1080.
2. Heo MY, Sohn SJ, Au WW: Anti-genotoxicity of galangin as a cancer chemopreventive agent candidate. Mutat Res 2001, 488:135-150.
3. Rotelli AE, Guardia T, Juarez AO, de la Rocha NE, Pelzer LE: Comparative study of flavonoids in experimental models of inflammation. Pharmacol Res 2003, 48:601-606.
4. Yochum L, Kushi L, Meyer K, Folsom A: Dietary flavonoid intake and risk of cardiovascular disease in postmenopausal women. Am J Epidemiol 1999, 149:943-945.
5. Mukhopadhyay A, Banerjee S, Stafford LJ, Xia C, Liu M, Aggarwal BB: Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene 2002, 21:8852-8861.
6. Kinghorn AD, Su BN, Jang DS, Chang LC, Lee D, Gu JQ, Carcache-Blanco EJ, Pawlus AD, Lee SK, Park EJ, et al.: Natural inhibitors of carcinogenesis. Planta Med 2004, 70:691-705.
7. Li BH, Tian WX: Presence of fatty acid synthase inhibitors in the rhizome of Alpinia officinarum hance. J Enzyme Inhib Med Chem 2003, 18:349-356.
8. Volpi N: Separation of flavonoids and phenolic acids from propolis by capillary zone electrophoresis. Electrophoresis 2004, 25:1872-1878.
9. Borrelli F, Maffia P, Pinto L, Ianaro A, Russo A, Capasso F, Ialenti A: Phytochemical compounds involved in the anti-inflammatory effect of propolis extract. Fitoterapia 2002, 73 (Suppl 1):S53-63.
10. So FV, Guthrie N, Chambers AF, Carroll KK: Inhibition of proliferation of estrogen receptor-positive MCF-7 human breast cancer cells by flavonoids in the presence and absence of excess estrogen. Cancer Lett 1997, 112:127-133.
11. Blonska M, Bronikowska J, Pietsz G, Czuba ZP, Scheller S, Krol W: Effects of ethanol extract of propolis (EEP) and its flavones on inducible gene expression in J774A.1 macrophages. J Ethnopharmacol 2004, 91:25-30.
12. O'Leary KA, de Pascual-Tereasa S, Needs PW, Bao YP, O'Brien NM, Williamson G: Effect of flavonoids and vitamin E on cyclooxygenase-2 (COX-2) transcription. Mutat Res 2004, 551:245-254.
13. Amoros M, Simoes CM, Girre L, Sauvager F, Cormier M: Synergistic effect of flavones and flavonols against herpes simplex virus type 1 ln cell culture. Comparison with the antiviral activity of propolis. J Nat Prod 1992, 55:1732-1740.
14. Bosio K, Avanzini C, D'Avolio A, Ozino O, Savoia D: In vitro activity of propolis against Streptococcus pyogenes. Lett Appl Microbiol 2000, 31:174-177.
15. Quadri S, Qadri A, Mann KL, Sherr DH: The bioflavonoid galangin blocks aryl hydrocarbon receptor (AhR) activation and polycyclic aromatic hydrocarbon-induced pre-B cell apoptosis. Mol Pharmacol 2000, 58:515-525.
16. Trombino AF, Matulka RA, Yang S, Hafer LI, Rogers AE, Tosselli P, Kim D, Sonenshein GE, Near RI, Sherr DH: Expression of the aryl hydrocarbon receptor/transcription factor (AhR) and AhR-regulated CYP1 gene transcription in a rat model of mammary tumorigenesis. Breast Canc Res Treat 2000, 63:117-131.
17. Singletary K, Parker H, Milner J: Identification and in vivo formation of 32P-postlabeled rat mammary DMBA - DNA adducts. Carcinogenesis 1990, 11:1959-1963.
18. McDougal A, Wilson C, Safe S: Inhibition of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor growth by aryl hydrocarbon receptor agonists. Cancer Lett 1997, 120:53-63.
19. Gu YZ, Hogenesch JB, Bradfield CA: The PAS superfamily: sensors of environmental and developmental signals. Annu Rev Pharmacol Toxicol 2000, 40:519-561.
20. Liu C, Goshu E, Wells A, Fan CM: Identification of the downstream targets of SIM1 and ARNT2, a pair of transcription factors essential for neuroendocrine cell differentiation. J Biol Chem 2003, 278:44857-44867.
21. Chan W, Yao G, Gu Y, Bradfield C: Cross-talk between the aryl hydrocarbon receptor and hypoxia inducible factor signaling pathways. Demonstration of competition and compensation. J Biol Chem 1999, 274:12115-12123.
22. Maltepe E, Schmidt JV, Baunoch D, Bradfield CA, Simon MC: Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 1997, 386:403-407.
23. Poland A, Glover E, Bradfield CA: Characterization of polyclonal antibodies to the Ah receptor prepared by immunization with a synthetic peptide hapten. Mol Pharmacol 1990, 39:20-26.
24. Dolwick KM, Swanson HI, Bradfield CA: In vitro analysis of Ah receptor domains involved in ligand-activated DNA recognition. Proc Natl Acad Sci USA 1993, 90:8566-8570.
25. Chen HS, Perdew GH: Subunit composition of the heteromeric cytosolic aryl hydrocarbon receptor complex. J Biol Chem 1994, 269:27554.
26. Beischlag TV, Wang S, Rose DW, Torchia J, Reisz-Porszasz S, Muhammad K, Nelson WE, Probst MR, Rosenfeld MG, Hankinson O: Recruitment of the NCoA/ SRC-1/p160 family of transcriptional coactivators by the aryl hydrocarbon receptor/aryl hydrocarbon receptor nuclear translocator complex. Mol Cell Biol 2002, 22:4319-4333.
27. Hankinson O: The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol 1995, 35:307.
28. Kumar MB, Tarpey RW, Perdew GH: Differential recruitment of coactivator RIP140 by Ah and estrogen receptors. Absence of a role for LXXLL motifs. J Biol Chem 1999, 274:22155-22164.
29. Nguyen TA, Hoivik D, Lee JE, Safe S: Interactions of nuclear receptor coactivator/corepressor proteins with the aryl hydrocarbon receptor complex. Arch Biochem Biophys 1999, 367:250-257.
30. Rushing SR, Denison MS: The silencing mediator of retinoic acid and thyroid hormone receptors can interact with the aryl hydrocarbon (Ah) receptor but fails to repress Ah receptor-dependent gene expression. Arch Biochem Biophys 2002, 403:189-201.
31. Okey A, Riddick D, Harper P: The Ah receptor: mediator of the toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds. Toxicol Lett 1994, 70:1-22.
32. Porter W, Wang F, Duan R, Qin C, Castro-Rivera E, Kim K, Safe S: Transcriptional activation of heat shock protein 27 gene expression by 17beta-estradiol and modulation by antiestrogens and aryl hydrocarbon receptor agonists. J Mol Endocrinol 2001, 26:31-42.
33. Zhang S, Qin C, Safe SH: Flavonoids as aryl hydrocarbon receptor agonists/antagonists: effects of structure and cell context. Environ Health Perspect 2003, 111:1877-1882.
34. Whitlock JPJ: Genetic and molecular aspects of 2,3,7,8-tetrachlorodibenzo-p-dioxin action. Annu Rev Pharmacol Toxicol 1990, 30:251-277.
35. Larsen M, Angus WGR, Brake P, Eltom S, Jefcoate CR: CYP1B1 represents the major PAH-responsive P450 cytochrome constitutively expressed in normal primary HMEC. Fund Appl Tox 1997, 36:24.
36. Poland A, Glover E, Robinson J, Nebert D: Genetic expression of aryl hydrocarbon hydroxylase activity: induction of monooxygenase activites and cytochrome P1-450 formation by 2,3,7,8-tetrachlorodibenzo-p-dioxin in mice genetically "nonresponsive" to other aromatic hydrocarbons. J Biol Chem 1974, 249:5599-5606.
37. Carrier F, Owens R, Nebert D, Puga A: Dioxin-dependent activation of murine Cyp1a-1 gene transcription requires protein kinase C-dependent phosphorylation. Mol Cell Biol 1992, 12:1856-1863.
38. Buters JT, Sakai S, Richter T, Pineau T, Alexander DL, Savas U, Doehmer J, Ward JM, Jefcoate CR, Gonzalez FJ: Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethyl-benz[a]anthracene-induced lymphomas. Proc Natl Acad Sci USA 1999, 96:1977-1982.
39. Dertinger SD, Nazarenko DA, Silverstone AE, Gasiewicz TA: Aryl hydrocarbon receptor signaling plays a significant role in mediating benzo[a]pyrene- and cigarette smoke condensate-induced cytogenetic damage in vivo. Carcinogenesis 2001, 22:171-177.
40. Abdelrahim M, Smith R 3rd, Safe S: Aryl hydrocarbon receptor gene silencing with small inhibitory RNA differentially modulates Ah-responsiveness in MCF-7 and HepG2 cancer cells. Mol Pharmacol 2003, 63:1373-1381.
41. Puga A, Barnes SJ, Dalton TP, Chang C, Knudsen ES, Maier MA: Aromatic hydrocarbon receptor interaction with the retinoblastoma protein potentiates repression of E2F-dependent transcription and cell cycle arrest. J Biol Chem 2000, 275:2943-2950.
42. Puga A, Xia Y, Elferink C: Role of the aryl hydrocarbon receptor in cell cycle regulation. Chem Biol Interact 2002, 141:117-130.
43. Ge NL, Elferink CJ: A direct interaction between the aryl hydrocarbon receptor and retinoblastoma protein. Linking dioxin signaling to the cell cycle. J Biol Chem 1998, 273:22708-22713.
44. Ma Q, Whitlock J: The aromatic hydrocarbon receptor modulates the Hepa 1c1c7 cell cycle and differentiated state independently of dioxin. Mol Cell Biol 1996, 16:2144-2150.
45. Beischlag TV, Perdew GH: ER alpha-AHR-ARNT protein-protein interactions mediate estradiol-dependent transrepression of dioxin-inducible gene transcription. J Biol Chem 2005, 280:21607-21611.
46. Weiss C, Kolluri SK, Kiefer F, Gottlicher M: Complementation of Ah receptor deficiency in hepatoma cells: negative feedback regulation and cell cycle control by the Ah receptor. Exp Cell Res 1996, 226:154-163.
47. Ohtake F, Takeyama K, Matsumoto T, Kitagawa H, Yamamoto Y, Nohara K, Tohyama C, Krust A, Mimura J, Chambon P, et al.: Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. Nature 2003, 423:545-550.
48. Matikainen TM, Moriyama T, Morita Y, Perez GI, Korsmeyer SJ, Sherr DH, Tilly JL: Ligand activation of the aromatic hydrocarbon receptor transcription factor drives Bax-dependent apoptosis in developing fetal ovarian germ cells. Endocrinology 2002, 143:615-620.
49. Caruso JA, Mathieu PA, Joiakim A, Leeson B, Kessel D, Sloane BF, Reiners JJ Jr: Differential susceptibilities of murine hepatoma 1c1c7 and Tao cells to the lysosomal photosensitizer NPe6: influence of aryl hydrocarbon receptor on lysosomal fragility and protease contents. Mol Pharmacol 2004, 65:1016-1028.
50. Safe S: Molecular biology of the Ah receptor and its role in carcinogenesis. Toxicol Lett 2001, 120:1-7.
51. Ciolino H, Yeh G: The flavonoid galangin is an inhibitor of CYP 1A1 activity and an agonist of the AhR. Br J Cancer 1999, 79:1340-1346.
52. Sheehan DM: The case for expanded phytoestrogen research. Proc Soc Exp Biol Med 1995, 208:3-5.
53. Karchner SI, Franks DG, Powell WH, Hahn ME: Regulatory interactions among three members of the vertebrate aryl hydrocarbon receptor family: AHR repressor, AHR1, and AHR2. J Biol Chem 2002, 277:6949-6959.
54. Yang X, Liu D, Murray T, Mitchell G, Hestermann D, Karchner S, Merson R, Hahn M, Sherr D: The aryl hydrocarbon receptor constitutively represses c-myc transcription in human mammary tumor cells. Oncogene 2005, 24:7869.
55. Han D, Nagy SR, Denison MS: Comparison of recombinant cell bioassays for the detection of Ah receptor agonists. Biofactors 2004, 20:11-22.
56. Schlezinger JJ, Jensen BA, Mann KK, Ryu HY, Sherr DH: Peroxisome Proliferator-Activated Receptor g-Mediated NF-kB Activation and Apoptosis in Pre-B Cells. J Immunol 2002, 169:6831-6841.
57. Yamaguchi K, Near RI, Matulka RA, Shneider A, Toselli P, Trombino AF, Sherr DH: Activation of the aryl hydrocarbon receptor/transcription factor and bone marrow stromal celldependent preB cell apoptosis. J Immunol 1997, 158:2165-2173.
58. WAF1 reveals a death pathway distinct from clonal deletion. J Immunol 2003, 170:4897-4904.
59. Hayashibara T, Yamada Y, Mori N, Harasawa H, Sugahara K, Miyanishi T, Kamihira S, Tomonaga M: Possible involvement of aryl hydrocarbon receptor (AhR) in adult T-cell leukemia (ATL) leukemogenesis: constitutive activation of AhR in ATL. Biochem Biophys Res Commun 2003, 300:128-134.
60. Koliopanos A, Kleeff J, Xiao Y, Safe S, Zimmermann A, Buchler MW, Friess H: Increased arylhydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer. Oncogene 2002, 21:6059-6070.
61. Singh SS, Hord NG, Perdew GH: Characterization of the activated form of the aryl hydrocarbon receptor in the nucleus of HeLa cells in the absence of exogenous ligand. Arch Biochem Biophys 1996, 329:47-55.
62. Wang X, Thomsen JS, Santostefano M, Rosengren R, Safe S, Perdew GH: Comparative properties of the nuclear aryl hydrocarbon (Ah) receptor complex from several human cell lines. Eur J Pharmacol 1995, 293:191-205.
63. Chang CY, Puga A: Constitutive activation of the aromatic hydrocarbon receptor. Mol Cell Biol 1998, 18:525-535.
64. Wang WL, Thomsen JS, Porter W, Moore M, Safe S: Effect of transient expression of the oestrogen receptor on constitutive and inducible CYP1A1 in Hs578T human breast cancer cells. Br J Cancer 1996, 73:316-322.
65. Gasiewicz RA, Rucci G: a-Naphthoflavone acts as an antagonist of 2,3,7,8-tetrachlorodibenzo-p-dioxin by forming an inactive complex with the Ah receptor. Molec Pharmacol 1991, 40:607-612.
66. Yamaguchi K, Matulka RA, Shneider AM, Toselli P, Trombino AF, Yang S, Hafer LJ, Mann KK, Tao XJ, Tilly JL, et al.: Induction of PreB cell apoptosis by 7,12-dimethylbenz[a]anthracene in long-term primary murine bone marrow cultures. Toxicol Appl Pharmacol 1997, 147:190-203.
67. Seeger H, Diesing D, Guckel B, Wallwiener D, Mueck AO, Huober J: Effect of tamoxifen and 2-methoxyestradiol alone and in combination on human breast cancer cell proliferation. J Steroid Biochem Mol Biol 2003, 84:255-257.
68. Safe S, McDougal A: Mechanism of action and development of selective aryl hydrocarbon receptor modulators for treatment of hormone-dependent cancers (Review). Int J Oncol 2002, 20:1123-1128.
69. Cover CM, Hsieh SJ, Tran SH, Hallden G, Kim GS, Bjeldanes LF, Firestone GL: Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J Biol Chem 1998, 273:3838-3847.
70. Mimura J, Ema M, Sogawa K, Fujii-Kuriyama Y: Identification of a novel mechanism of regulation of Ah (dioxin) receptor function. Genes Dev 1999, 13:20-25.
71. Baba T, Mimura J, Gradin K, Kuroiwa A, Watanabe T, Matsuda Y, Inazawa J, Sogawa K, Fujii-Kuriyama Y: Structure and expression of the Ah receptor repressor gene. J Biol Chem 2001, 276:33101-33110.
72. Watanabe T, Imoto I, Kosugi Y, Fukuda Y, Mimura J, Fujii Y, Isaka K, Takayama M, Sato A, Inazawa J: Human arylhydrocarbon receptor repressor (AHRR) gene: genomic structure and analysis of polymorphism in endometriosis. J Hum Genet 2001, 46:342-346.
73. Korkalainen M, Tuomisto J, Pohjanvirta R: Primary structure and inducibility by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) of aryl hydrocarbon receptor repressor in a TCDD-sensitive and a TCDD-resistant rat strain. Biochem Biophys Res Commun 2004, 315:123-131.
74. Ma Y, Yuan J, Huang M, Jove R, Cress WD: Regulation of the cyclin D3 promoter by E2F1. J Biol Chem 2003, 278:16770-16776.
75. Mazumder S, DuPree EL, Almasan A: A dual role of cyclin E in cell proliferation and apoptosis may provide a target for cancer therapy. Curr Cancer Drug Targets 2004, 4:65-75.
76. Yam CH, Fung TK, Poon RY: Cyclin A in cell cycle control and cancer. Cell Mol Life Sci 2002, 59:1317-1326.
77. Sutherland RL, Musgrove EA: Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 2004, 9:95-104.
78. Sutherland RL, Musgrove EA: Cyclin E and prognosis in patients with breast cancer. N Engl J Med 2002, 347:1546-1547.
79. Russell A, Thompson MA, Hendley J, Trute L, Armes J, Germain D: Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer. Oncogene 1999, 18:1983-1991.
80. Marlowe JL, Knudsen ES, Schwemberger S, Puga A: The aryl hydrocarbon receptor displaces p300 from E2F-dependent promoters and represses S-phase specific gene expression. J Biol Chem 2004.
81. Allan LL, Sherr DH: Constitutive activation and environmental chemical induction of the aryl hydrocarbon receptor/transcription factor in activated human B lymphocytes. Mol Pharmacol 2005, 67:1740-1750.
82. Wang F, Wang W, Safe S: Regulation of constitutive gene expression through interactions of Sp1 protein with the nuclear aryl hydrocarbon receptor complex. Biochemistry 1999, 38:11490-11500.
83. Corton JC: Overlapping but unique DNA binding specificites of the Ah receptor and constitutive dioxin-responsive element binding proteins from human keratinocytes. Toxicol Lett 1996, 85:67-75.
84. Levine-Fridman A, Chen L, Elferink CJ: Cytochrome P4501A1 promotes G1 phase cell cycle progression by controlling aryl hydrocarbon receptor activity. Mol Pharmacol 2004, 65:461-469.
85. Pirkmaier A, Dow R, Ganiatsas S, Waring P, Warren K, Thompson A, Hendley J, Germain D: Alternative mammary oncogenic pathways are induced by D-type cyclins; MMTV-cyclin D3 transgenic mice develop squamous cell carcinoma. Oncogene 2003, 22:4425-4433.
86. Wong SC, Chan JK, Lee KC, Hsiao WL: Differential expression of p16/p21/ p27 and cyclin D1/D3, and their relationships to cell proliferation, apoptosis, and tumour progression in invasive ductal carcinoma of the breast. J Pathol 2001, 194:35-42.
87. Sarcevic B, Lilischkis R, Sutherland RL: Differential phosphorylation of T-47D human breast cancer cell substrates by D1-, D3-, E-, and A-type cyclin-CDK complexes. J Biol Chem 1997, 272:33327-33337.
88. Arnold A, Papanikolaou A: Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 2005, 23:4215-4224.